Novel therapeutic strategies for treatment of liver cancer

Authors

  • Vimalavathini R. Department of Pharmacology, College of Pharmacy, MTPG & RIHS, Pondicherry
  • Marthiyana Begum M Department of Pharmacology, College of Pharmacy, MTPG & RIHS, Pondicherry
  • Suganthi A Department of Pharmacology, College of Pharmacy, MTPG & RIHS, Pondicherry
  • Vimalrai T Department of Pharmacology, College of Pharmacy, MTPG & RIHS, Pondicherry
  • Kavimani S. Department of Pharmacology, College of Pharmacy, MTPG & RIHS, Pondicherry

DOI:

https://doi.org/10.7439/ijpr.v7i5.4147

Abstract

Liver cancer is the most common type of solid tumor with poor prognosis. Various environmental, genetic and epigenetic factors including aberrant molecular signaling pathways play a significant role in pathogenesis of liver cancer. Targeting these molecular pathways has paved the way for evolution of molecular targeted drugs. Liver being less immunogenic strategies to improve immunosurveillance evasion by cancer cells has been addressed using immunotherapy. Research on novel therapeutic strategies such as immunotherapy, molecular targeted therapy, gene therapy is ongoing. This review aims to discuss current trends and recent developments in the field of liver cancer therapy.

Downloads

Download data is not yet available.

Author Biography

  • Vimalavathini R., Department of Pharmacology, College of Pharmacy, MTPG & RIHS, Pondicherry

    Assistant professor

    Department of Pharmacology

    College of Pharmacy

    MTPG & RIHS

    Pondicherry

References

Pascual S, Herrea I, Irurzun J. New advances in hepatocellular carcinoma. World J Hepatol 2016; 8(9): 421-38.

Terry K, Copur MS. Molecular targeted therapy of hepatocellular carcinoma. Journal of Cancer Therapy, 2013;4:426-39.

Tsuchiya N, Sawada Y, Endo I, Uemura Y, Nakatsura T. Potentiality of immunotherapy against hepatocellular carcinoma. World J Gastroenteral 2015; 21(36): 10314-26.

Li S, Yang F, Ren X. Immunotherapy for hepatocellular carcinoma. Drug Discoveries and Therapeutics.2015; 9(5):363-71.

Avila MA, Berasain C, Sangro B, Prieto J. New therapies for hepatocellular carcinoma. Oncogene. 2006 ;25(27):3866-84.

Llovet JM, Bruix JD. Molecular targeted therapies in hepatocellular carcinoma. Hepatology. 2008;48(4):1312

Connock M, Round J, Bayliss S, Tubeuf S, Greenheld W, Moore D. Sorafenib for the treatment of advanced hepatocellular carcinoma. Health Technol Assess. 2010;14 Suppl 1:17-21.

Shin JW, Chung Y. Molecular targeted therapy for hepatocellular carcinoma: Current and future. World J Gastroenterol, 2013; 19(37): 6144-55.

Wang C, Wey K, Mo L, Chang K, Lin R, Kuo J. Current trends and recent advances in diagnosis, therapy and prevention of hepatocellular carcinoma. Asian Pac J Cancer Prev. 2015;16(9):3595-604.

Schlachterman A, Craft WW, Hilgenfeldt E, Mitra A, Cabrera R. Current and future treatments for hepatocellular carcinoma. World J Gastroenterol 2015;21(28): 8478-91.

Gong XL, Qin S. Progress in systemic therapy of advanced hepatocellular carcinoma. World J Gastroenterol. 2016;22(29):6582

Chen C, Wang G. Mechanism of HCC and challenges and opportunities for molecular targeted therapy. World J Hepatol.2015; 7(15): 1964-70.

Greten TF, Manns MP, Korangy F. Immunotherapy of hepatocellular carcinoma, J Hepatol. 2006;45(6):868-78.

Aravalli R, Steer CJ. Immune-Mediated Therapies for Liver Cancer. Genes (Basel). 2017;8(2). doi: 10.3390/genes8020076.

Willimsky G, Protzer U, Knolle P, Heikenwalder M. Adoptive T-cell therapy to treat liver cancer: Is the liver microenvironment key? Oncotarget 2013;4(8):1117-8.

Sangiolo D. Cytokine induced killer cells as promising immunotherapy for solid tumors. Journal of Cancer 2011, 2:363-8.

Kudo M. Immune checkpoint inhibition in hepatocellular carcinoma: Basics and ongoing clinical trials. Oncology 2017;92(suppl 1):50

Hern

Downloads

Published

2017-06-01

Issue

Vol. 7 No. 5 (2017): May

Section

Review Article

License

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
    3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
    4. Author must Submit Copyright form  After acceptance of Article

How to Cite

1.
R. V, M MB, A S, T V, S. K. Novel therapeutic strategies for treatment of liver cancer. Int J of Pharmc Res [Internet]. 2017 Jun. 1 [cited 2024 Oct. 18];7(5):99-102. Available from: https://ssjournals.co.in/index.php/ijpr/article/view/4147

Most read articles by the same author(s)

<< < 28 29 30 31 32 33 34 35 36 > >>